Search International and National Patent Collections

1. (WO2014010603) PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING STRESS URINARY INCONTINENCE OR MIXED INCONTINENCE, AND METHOD FOR SCREENING COMPOUNDS TO BE INCLUDED IN SAID PHARMACEUTICAL COMPOSITION

Pub. No.:    WO/2014/010603    International Application No.:    PCT/JP2013/068781
Publication Date: Fri Jan 17 00:59:59 CET 2014 International Filing Date: Wed Jul 10 01:59:59 CEST 2013
IPC: G01N 33/15
A61K 31/343
A61K 31/381
A61K 31/4045
A61K 45/00
A61P 7/12
A61P 43/00
C12Q 1/02
G01N 33/50
C12N 15/09
Applicants: ASTELLAS PHARMA INC.
アステラス製薬株式会社
Inventors: WATANABE, Toru
渡辺 亨
KAWABATA, Keiko
川端 圭子
WATANABE, Yuka
渡辺 由香
YUYAMA, Hironori
湯山 弘法
MASUDA, Noriyuki
増田 典之
BURGARD, Edward C.
バーガード、エドワード シー
THOR, Karl Bruce
トール、カール ブルース
Title: PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING STRESS URINARY INCONTINENCE OR MIXED INCONTINENCE, AND METHOD FOR SCREENING COMPOUNDS TO BE INCLUDED IN SAID PHARMACEUTICAL COMPOSITION
Abstract:
[Problem] To provide a pharmaceutical composition for treating or preventing urinary incontinence on the basis of a novel mechanism of action, and a method for screening compounds to be included in the pharmaceutical composition as the active ingredient. [Solution] The present invention pertains to a pharmaceutical composition for treating or preventing stress urinary incontinence or mixed incontinence and containing as the active ingredient a compound having a melatonin receptor activation effect. Melatonin, ramelteon, agomelatine, tasimelteon, TIK-301, and the like can be cited as the active ingredient. Also, the present invention pertains to a method that is for screening compounds to be included as the active ingredient in the pharmaceutical composition for treating or preventing stress urinary incontinence or mixed incontinence and that comprises: a step for measuring melatonin receptor activity; a step for measuring the contraction of an excised urethra; and a step for measuring urethral inner pressure.